Literature DB >> 22966500

Magnesium and the inflammatory response: potential pathophysiological implications in the management of patients with aneurysmal subarachnoid hemorrhage?

Carl Muroi1, Jan-Karl Burkhardt, Michael Hugelshofer, Martin Seule, Kenichi Mishima, Emanuela Keller.   

Abstract

Cerebral vasospasm and delayed cerebral ischemia remain an unsolved problem in patients with aneurysmal subarachnoid hemorrhage (SAH). In theory, high-dose magnesium sulfate (MgSO(4)) therapy offers vascular and neuroprotective benefits and is therefore currently under evaluation. The intensity of the inflammatory response after SAH is associated with the outcome. The aim of the current study was to evaluate a possible link between the inflammatory response and MgSO(4) therapy, since magnesium (Mg(2+)) has anti-inflammatory properties. In 15 patients with SAH, inflammatory cytokine levels in the cerebrospinal fluid (CSF) and peripheral blood were determined daily using an enzyme-linked immunosorbent assay between day 4 and day 12. Eight patients were treated with standard therapy alone (group 1) and seven patients were treated with an additional, high-dose of MgSO(4) (group 2). Serum Mg(2+) levels in group 2 were significantly higher compared to group 1: 1.48 ± 0.04 mmol/L versus 0.90 ± 0.01 mmol/L, ρ<0.001. Interleukin-6 (IL-6) in the CSF was significantly lower in group 2 compared to group 1: 6680 ± 989 vs.11079 ± 1277 pg/mL, ρ = 0.021. A trend towards lower systemic IL-6 levels was found in group 2: 58 ± 7 versus 104 ± 21 pg/mL, ρ = 0.052. Systemic IL-1β levels were significantly lower in group 2: 0.66 ± 0.11 and 0.15 ± 0.01 pg/mL (ρ<0.001), while the CSF levels did not differ. Tumor necrosis factor-α levels did not differ between the two groups. Although there were more patients with favorable outcome in group 2, the difference was not statistically significant. This was probably due to the small sample size. The results indicate a suppression of inflammatory cytokine release, in particular IL-6, in patients treated with high-dose MgSO(4). These results call for further studies of the effect of Mg(2+) on the inflammatory signaling pathway with regard to delayed cerebral ischemia following SAH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22966500

Source DB:  PubMed          Journal:  Magnes Res        ISSN: 0953-1424            Impact factor:   1.115


  8 in total

1.  Magnesium Sulfate Provides Neuroprotection in Eclampsia-Like Seizure Model by Ameliorating Neuroinflammation and Brain Edema.

Authors:  Xiaolan Li; Xinjia Han; Jinying Yang; Junjie Bao; Xiaodan Di; Guozheng Zhang; Huishu Liu
Journal:  Mol Neurobiol       Date:  2016-11-22       Impact factor: 5.590

2.  Cerebral vasospasm pharmacological treatment: an update.

Authors:  Ioannis Siasios; Eftychia Z Kapsalaki; Kostas N Fountas
Journal:  Neurol Res Int       Date:  2013-01-31

Review 3.  Inflammation, cerebral vasospasm, and evolving theories of delayed cerebral ischemia.

Authors:  Kevin R Carr; Scott L Zuckerman; J Mocco
Journal:  Neurol Res Int       Date:  2013-08-22

4.  Intravenous magnesium sulfate for the management of severe hand, foot, and mouth disease with autonomic nervous system dysregulation in Vietnamese children: study protocol for a randomized controlled trial.

Authors:  Phan Tu Qui; Truong Huu Khanh; Huynh Trung Trieu; Phạm Thanh Giang; Nguyen Ngọc Bich; Le Phan Kim Thoa; Le Nguyen Thanh Nhan; Saraswathy Sabanathan; Rogier Van Doorn; Nguyen Duc Toan; Laura Merson; Nguyen Thi Phuong Dung; Lam Phung Khanh; Marcel Wolbers; Nguyen Thanh Hung; Nguyen Van Vinh Chau; Bridget Wills
Journal:  Trials       Date:  2016-02-19       Impact factor: 2.279

5.  Magnesium lithospermate B, an active extract of Salvia miltiorrhiza, mediates sGC/cGMP/PKG translocation in experimental vasospasm.

Authors:  Chih-Zen Chang; Shu-Chuan Wu; Aij-Lie Kwan
Journal:  Biomed Res Int       Date:  2014-04-02       Impact factor: 3.411

Review 6.  The role of iron-induced fibrin in the pathogenesis of Alzheimer's disease and the protective role of magnesium.

Authors:  Boguslaw Lipinski; Etheresia Pretorius
Journal:  Front Hum Neurosci       Date:  2013-10-29       Impact factor: 3.169

Review 7.  To look beyond vasospasm in aneurysmal subarachnoid haemorrhage.

Authors:  Giulia Cossu; Mahmoud Messerer; Mauro Oddo; Roy Thomas Daniel
Journal:  Biomed Res Int       Date:  2014-05-19       Impact factor: 3.411

8.  Effects of stellate ganglion block on early brain injury in patients with subarachnoid hemorrhage: a randomised control trial.

Authors:  Jian Zhang; Ying Nie; Qiongni Pang; Xubiao Zhang; Qianting Wang; Jing Tang
Journal:  BMC Anesthesiol       Date:  2021-01-20       Impact factor: 2.217

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.